Overview
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
Status:
Completed
Completed
Trial end date:
2009-09-01
2009-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Chugai PharmaceuticalTreatments:
Epoetin Alfa
Criteria
Inclusion Criteria:- Lung cancer or gynecologic cancer patients
- Undergoing platinum-based chemotherapy repeated for ≧ 2 cycles after erythropoietin
(EPO) or placebo administration
- 8.0 g/dL ≦ hemoglobin concentration (Hb) ≦ 10.0 g/dL
- 20 - 79 years old
- Performance status: 0 - 2
- No iron deficiency anemia
Exclusion Criteria:
- Red blood cell transfusion within 4 weeks before treatment
- Erythropoietin therapy within 8 weeks before treatment